DR. STEVEN N MONTGOMERY M.D.
Prescription History 1790736031
Ophthalmology in Las Vegas, NV


Quality Rating: 92.62 out of 100 score

NPI Status: Active since May 12, 2006

Contact Information

3575 PECOS MCLEOD
LAS VEGAS, NV
ZIP 89121
Phone: (702) 731-2088
Fax: (702) 734-7836

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. STEVEN N MONTGOMERY M.D., an active Ophthalmology specialist practicing in Las Vegas, NV. Our medical registry currently tracks 12 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 858 documented patient claims. Among these therapy options, the most frequently utilized medication is Latanoprost, which accounts for 322 claims alone.


Dexamethasone Sodium Phosphate

Generic Formulation: Dexamethasone Sodium PhosphateSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 86
30-Day Fills 101.0
Days Supply 2,239
NV State Average Benchmarks
Peer Average Claims75.0
Peer Average 30-Day Fills94.5
Peer Average Days Supply2,254
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NV. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,079.08 across this reporting matrix range.

Provider Avg Cost Per Claim

$35.80

State Avg Cost Per Claim

$49.93

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Dexamethasone is used to treat conditions such as arthritis, blood/hormone disorders, allergic reactions, skin diseases, eye problems, breathing problems, bowel disorders, cancer, and immune system disorders. It is also used as a test for an adrenal gland disorder (Cushing's syndrome). Dexamethasone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions. This injectable form of dexamethasone is used when a similar drug cannot be taken by mouth or when a very fast response is needed, especially in patients with severe medical conditions. Talk to your doctor about the risks and benefits of dexamethasone, especially if it is to be injected near your spine (epidural). Rare but serious side effects may occur with epidural use.

Dorzolamide Hcl

Generic Formulation: Dorzolamide HclSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 11
30-Day Fills 33.3
Days Supply 1,000
NV State Average Benchmarks
Peer Average Claims56.0
Peer Average 30-Day Fills123.0
Peer Average Days Supply3,673
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 80.4% less volume than the regional standard for practitioners inside NV. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $193.43 across this reporting matrix range.

Provider Avg Cost Per Claim

$17.58

State Avg Cost Per Claim

$29.71

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Dorzolamide is used to treat high pressure inside the eye due to glaucoma (open angle-type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This medication works by decreasing the amount of fluid within the eye. It belongs to a class of drugs known as carbonic anhydrase inhibitors.

Dorzolamide-Timolol

Generic Formulation: Dorzolamide Hcl/Timolol MaleatSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 31
30-Day Fills 94.6
Days Supply 2,838
NV State Average Benchmarks
Peer Average Claims98.0
Peer Average 30-Day Fills223.0
Peer Average Days Supply6,670
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 68.4% less volume than the regional standard for practitioners inside NV. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $899.45 across this reporting matrix range.

Provider Avg Cost Per Claim

$29.01

State Avg Cost Per Claim

$29.63

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product contains two drugs used to treat high pressure inside the eye due to glaucoma (open angle-type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This medication works by decreasing the amount of fluid within the eye. Timolol belongs to a class of drugs known as beta-blockers, and dorzolamide belongs to a class of drugs known as carbonic anhydrase inhibitors.

Erythromycin

Generic Formulation: Erythromycin BaseSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 41
30-Day Fills 41.0
Days Supply 691
NV State Average Benchmarks
Peer Average Claims74.0
Peer Average 30-Day Fills77.4
Peer Average Days Supply1,087
Conservative Utilization

This provider writes prescriptions for this formulation 44.6% less frequently than the standard regional baseline metric for practitioners inside NV. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $382.45 across this reporting matrix range.

Provider Avg Cost Per Claim

$9.33

State Avg Cost Per Claim

$11.87

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Erythromycin is used to treat a wide variety of bacterial infections. It may also be used to prevent certain bacterial infections. Erythromycin is known as a macrolide antibiotic. It works by stopping the growth of bacteria. This antibiotic treats or prevents only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Flurbiprofen Sodium

Generic Formulation: Flurbiprofen SodiumSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 71
30-Day Fills 71.0
Days Supply 1,366
NV State Average Benchmarks
Peer Average Claims41.0
Peer Average 30-Day Fills47.2
Peer Average Days Supply1,114
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 73.2% higher than the standard regional baseline profile for NV. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,270.80 across this reporting matrix range.

Provider Avg Cost Per Claim

$46.07

State Avg Cost Per Claim

$72.28

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An anti-inflammatory analgesic and antipyretic of the phenylalkynoic acid series. It has been shown to reduce bone resorption in periodontal disease by inhibiting CARBONIC ANHYDRASE.

Therapeutic Applications

This medication is used before certain types of eye surgery (such as cataract removal). It prevents the pupil of the eye from narrowing. This effect makes it easier for the doctor to examine the inside of the eye, to remove the cataract, and to replace it with a new lens. Flurbiprofen belongs to a class of drugs known as nonsteroidal anti-inflammatory drugs (NSAIDs).

Latanoprost

Generic Formulation: LatanoprostSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 322
30-Day Fills 811.9
Days Supply 24,150
NV State Average Benchmarks
Peer Average Claims165.0
Peer Average 30-Day Fills350.0
Peer Average Days Supply10,249
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 95.2% higher than the standard regional baseline profile for NV. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $8,361.25 across this reporting matrix range.

Provider Avg Cost Per Claim

$25.97

State Avg Cost Per Claim

$25.56

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A prostaglandin F analog used to treat OCULAR HYPERTENSION in patients with GLAUCOMA.

Therapeutic Applications

Latanoprost is used to treat high pressure inside the eye due to glaucoma (open angle type) or other eye diseases (such as ocular hypertension). It is similar to a natural chemical in the body (prostaglandin) and works by regulating the flow of fluid within the eye which results in lower pressure. Lowering high pressure inside the eye helps to prevent blindness.

Neomycin-Polymyxin-Dexameth

Generic Formulation: Neomycin/Polymyxin B/DexamethaSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 146
NV State Average Benchmarks
Peer Average Claims64.0
Peer Average 30-Day Fills66.8
Peer Average Days Supply984
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 81.3% less volume than the regional standard for practitioners inside NV. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $183.50 across this reporting matrix range.

Provider Avg Cost Per Claim

$15.29

State Avg Cost Per Claim

$15.25

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat conditions involving swelling (inflammation) of the eyes and to treat or prevent bacterial eye infections. This product contains neomycin and polymyxin, antibiotics that work by stopping the growth of bacteria. It also contains dexamethasone, an anti-inflammatory corticosteroid that works by reducing swelling. This medication treats/prevents only bacterial eye infections. It will not work for other types of eye infections and may worsen them (such as infections caused by viruses, fungi, mycobacteria). Unnecessary use or overuse of any antibiotic can lead to its decreased effectiveness.

Ofloxacin

Generic Formulation: OfloxacinSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 65
30-Day Fills 65.7
Days Supply 1,394
NV State Average Benchmarks
Peer Average Claims68.0
Peer Average 30-Day Fills72.8
Peer Average Days Supply1,637
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NV. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $725.05 across this reporting matrix range.

Provider Avg Cost Per Claim

$11.15

State Avg Cost Per Claim

$20.16

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.

Therapeutic Applications

This medication is used to treat eye infections. Ofloxacin belongs to a class of drugs called quinolone antibiotics. It works by stopping the growth of bacteria. This medication treats only bacterial eye infections. It will not work for other types of eye infections. Unnecessary use or overuse of any antibiotic can lead to its decreased effectiveness.

Polymyxin B Sul-Trimethoprim

Generic Formulation: Polymyxin B Sulf/TrimethoprimSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 41
30-Day Fills 52.6
Days Supply 1,431
NV State Average Benchmarks
Peer Average Claims41.0
Peer Average 30-Day Fills50.7
Peer Average Days Supply1,322
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NV. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $357.00 across this reporting matrix range.

Provider Avg Cost Per Claim

$8.71

State Avg Cost Per Claim

$8.55

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat bacterial infections (such as blepharitis, conjunctivitis) of the eye. It contains 2 antibiotics. Polymyxin B works by killing the bacteria. Trimethoprim works by stopping the growth of the bacteria. This medication treats only bacterial eye infections. It will not work for other types of eye infections. Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Prednisolone Acetate

Generic Formulation: Prednisolone AcetateSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 77
30-Day Fills 96.2
Days Supply 2,494
NV State Average Benchmarks
Peer Average Claims134.0
Peer Average 30-Day Fills171.0
Peer Average Days Supply4,381
Conservative Utilization

This provider writes prescriptions for this formulation 42.5% less frequently than the standard regional baseline metric for practitioners inside NV. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,981.33 across this reporting matrix range.

Provider Avg Cost Per Claim

$38.72

State Avg Cost Per Claim

$50.39

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain eye conditions due to inflammation or injury. Prednisolone works by relieving symptoms such as swelling, redness, and itching. It belongs to a class of drugs known as corticosteroids.

Restasis

Generic Formulation: CyclosporineSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 22
30-Day Fills 50.0
Days Supply 1,500
NV State Average Benchmarks
Peer Average Claims47.0
Peer Average 30-Day Fills85.8
Peer Average Days Supply2,568
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 53.2% less volume than the regional standard for practitioners inside NV. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $33,631.58 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,528.71

State Avg Cost Per Claim

$1,216.62

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A group of closely related cyclic undecapeptides from the fungi Trichoderma polysporum and Cylindocarpon lucidum. They have some antineoplastic and antifungal action and significant immunosuppressive effects. Cyclosporins have been proposed as adjuvants in tissue and organ transplantation to suppress graft rejection.

Therapeutic Applications

Cyclosporine eye drops are used to treat a certain type of dry eyes. They work by increasing the amount of tears you make.

Timolol Maleate

Generic Formulation: Timolol MaleateSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 79
30-Day Fills 179.9
Days Supply 5,392
NV State Average Benchmarks
Peer Average Claims90.0
Peer Average 30-Day Fills203.5
Peer Average Days Supply6,028
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NV. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $582.74 across this reporting matrix range.

Provider Avg Cost Per Claim

$7.38

State Avg Cost Per Claim

$21.52

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A beta-adrenergic antagonist that is similar in action to PROPRANOLOL; the levo-isomer is more active. Timolol has been proposed as an anti-hypertensive, anti-arrhythmic, anti-angina, and anti-glaucoma agent. It is also used in the treatment of MIGRAINE DISORDERS and tremor.

Therapeutic Applications

This medication is used to treat high pressure inside the eye due to glaucoma (open angle-type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This medication works by decreasing the amount of fluid within the eye. Timolol belongs to a class of drugs known as beta-blockers.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. STEVEN N MONTGOMERY M.D. provides transparency into local medical care patterns within Las Vegas, NV.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Ophthalmology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.